Primary Acquired Melanosis: Causes, Risks, and Care

If you’re searching for primary acquired melanosis, the direct answer is this: it is an acquired, flat, painless brown patch on the eye’s conjunctiva that can be either benign or precancerous, depending on whether abnormal cells (atypia) are present. According to research published in the National Library of Medicine (PMC), primary acquired melanosis accounted for 11% of all conjunctival tumors and 21% of melanocytic lesions in one large ocular oncology practice [1][7]. Understanding which type you have determines whether monitoring or treatment is needed.

What Primary Acquired Melanosis Actually Is

Primary acquired melanosis (PAM) is a pigmented lesion of the conjunctiva — the clear membrane covering the white of the eye and inner eyelids. It typically presents as a single, flat, brown patch in one eye, without cysts and without pain [1][3][6]. Unlike a congenital nevus, PAM is acquired, meaning it develops later in life rather than being present at birth. According to data summarized by EyeWiki, an Academy-affiliated reference maintained by ophthalmologists, PAM is most frequently identified in middle-aged, light-skinned individuals [2][6]. The lesion arises from melanocytes — pigment-producing cells — that begin proliferating within the conjunctival epithelium. The critical distinction is histologic: PAM without atypia behaves as a benign condition, while PAM with atypia is considered precancerous [2]. In a study of 311 eyes published in PMC, the lesion’s appearance alone could not reliably separate benign from precancerous forms, which is why a biopsy is often required for cases that change or expand [1]. This uncertainty is the central reason PAM warrants professional evaluation rather than self-monitoring.

How Doctors Classify PAM: With or Without Atypia

The single most important factor in primary acquired melanosis is whether the lesion contains atypia — abnormal melanocytes that signal cancer potential. According to the 311-eye study indexed in PMC, progression to melanoma occurred in 0% of PAM without atypia, 0% of PAM with mild atypia, and 13% of cases with severe atypia [1]. That gradient explains why pathologists grade these lesions so carefully. EyeWiki describes PAM with atypia as a precancerous lesion requiring closer management, while PAM without atypia is benign [2]. A board-certified ophthalmic pathologist examines tissue under a microscope to assess cell type, the depth of melanocyte spread within the epithelium, and the degree of nuclear abnormality. Kaplan-Meier estimates from the same PMC research projected melanoma transformation at 10 years in 12% of observed cases and 11% of biopsied cases [1]. Because grading drives every downstream decision — observation, surgical removal, or topical therapy — patients should ask specifically whether atypia was identified and at what severity. Without that detail, a brown conjunctival spot cannot be properly risk-stratified, and a general “melanosis” label tells you very little about your actual cancer risk.

How Serious Is the Cancer Risk?

The cancer concern with primary acquired melanosis is real but graded. Research published in ARVO’s IOVS journal reports that conjunctival melanoma arises from pre-existing PAM in 71–74% of cases, making PAM the most common precursor lesion [2][10]. However, the prognosis for melanomas that originate from PAM is notably better than for those arising de novo. According to the IOVS data, melanoma-related death at 10 years was 9% for tumors originating from PAM, compared with 35% for melanomas that developed without a precursor lesion [10]. That four-fold difference underscores why early identification of PAM — even before any malignant change — has measurable survival value. The U.S. National Cancer Institute classifies conjunctival melanoma as a rare ocular cancer, and PAM screening is one of the few opportunities to catch the precursor stage. For patients, the practical takeaway is that severe atypia, documented growth, or change in pigmentation are the warning signs that move a lesion from “watch” to “treat.” A flat brown patch that has been stable and graded without atypia carries a very different risk profile than one with severe atypia and recent expansion.

How PAM Is Diagnosed and Documented

Diagnosis of primary acquired melanosis begins with a slit-lamp examination by an ophthalmologist, who maps the lesion’s location, size, and pigment distribution. According to the American Academy of Ophthalmology (AAO), careful documentation — including baseline photography — is central to managing pigmented conjunctival lesions because change over time is the key risk indicator [4]. Anterior segment optical coherence tomography (OCT) adds cross-sectional imaging; PMC research correlating OCT with histopathology found imaging useful for characterizing lesion architecture [7]. The definitive answer, however, comes from a biopsy. For lesions covering more than 3–4 clock hours of the conjunctiva or showing suspicious features, surgeons may perform a mapping biopsy to sample multiple zones. A typical U.S. out-of-pocket cost range for an ophthalmology consultation plus slit-lamp evaluation runs $150–$400 without insurance, while a conjunctival biopsy with pathology can range $800–$2,500 depending on facility and region. Costs vary by state and whether the procedure occurs in an office, surgery center, or hospital outpatient setting. Patients with vision or medical coverage should confirm whether the biopsy is billed under their medical plan rather than a vision rider, since the two cover ophthalmic procedures differently.

Treatment Options and Typical US Costs

Treatment of primary acquired melanosis depends entirely on the atypia grade. PAM without atypia is generally observed with periodic photography rather than removed, since PMC data showed 0% progression in this group [1]. PAM with atypia — particularly severe atypia, where 13% progressed to melanoma — is treated more aggressively [1]. According to the AAO, common approaches include surgical excision with cryotherapy to the lesion margins, and topical chemotherapy using mitomycin C eye drops for diffuse disease [4]. Surgical excision with cryotherapy in a U.S. ambulatory surgery setting commonly ranges $2,000–$6,000 before insurance, while a course of topical mitomycin C may range $300–$900 for the medication plus monitoring visits. These figures vary by state, surgeon, and facility type. Because conjunctival melanoma is rare, the U.S. Food and Drug Administration (FDA) has not approved a drug specifically for PAM, so mitomycin C is used off-label under ophthalmologist supervision — a detail patients should confirm before starting. Insurance coverage for medically necessary excision is generally available when pathology documents atypia, but pre-authorization requirements differ across Medicare, Medicaid, and private carriers. Always request an itemized estimate and verify network status before scheduling.

How to Choose Between Observation and Treatment

Deciding whether to monitor or treat primary acquired melanosis is a shared decision between you and an ocular oncology specialist, anchored to the biopsy grade. If pathology shows PAM without atypia, the evidence supports observation: the 311-eye PMC study recorded 0% melanoma progression in this group, so repeat photography every 6–12 months is a reasonable plan [1]. If pathology shows severe atypia, the 13% progression rate argues for definitive treatment such as excision with cryotherapy [1][4]. Three questions should guide the conversation: What is my exact atypia grade? How many clock hours of conjunctiva are involved? Has the lesion changed since the last photograph? Patients should also weigh access — referral to a fellowship-trained ocular oncologist may require travel, since these specialists practice in a limited number of U.S. centers. Verify a physician’s credentials through the American Board of Ophthalmology’s online “Find a Physician” verification tool before committing to a treatment plan. A second opinion is reasonable for any recommendation involving surgery, and the AAO supports baseline and follow-up imaging as the standard for tracking pigmented conjunctival lesions over time [4].

Red Flags and When to See a Specialist

Certain changes in primary acquired melanosis warrant prompt evaluation rather than waiting for an annual exam. Schedule an ophthalmology visit within weeks if you notice: a flat brown conjunctival patch that is enlarging, darkening, or developing a raised nodule; new blood vessels feeding the lesion; or pigment spreading onto the cornea or eyelid margin. According to ARVO’s IOVS research, the presence of nodularity or thickening can signal transformation toward melanoma, which arises from PAM in 71–74% of cases [10]. Because melanoma-related death at 10 years was 9% for PAM-origin tumors versus 35% for de novo melanomas, early specialist referral measurably improves outcomes [10]. Do not rely on over-the-counter products or telehealth photo apps to assess an eye lesion; these are not validated diagnostic tools. If you suspect a delay or denial harmed your care, the U.S. Better Business Bureau and your state medical board accept complaints against providers, and CMS regulates Medicare appeal rights. A flat patch that has been stable for years and graded without atypia is low risk — but any documented change resets that assessment and justifies re-imaging or repeat biopsy.

What Experts Recommend

Ocular oncology specialists and the American Academy of Ophthalmology converge on a few core principles for managing primary acquired melanosis. First, baseline photographic documentation is recommended for every pigmented conjunctival lesion, because change over time — not a single snapshot — is the most reliable warning sign [4]. Second, experts emphasize histologic grading: management hinges on whether atypia is present and how severe it is, given the 0% versus 13% progression spread reported in PMC research [1]. Third, specialists generally favor observation for PAM without atypia and excision with cryotherapy or topical mitomycin C for atypical disease, reserving aggressive intervention for documented severe atypia [4]. As of 2026, there is no FDA-approved drug marketed specifically for PAM, so any topical chemotherapy is administered off-label under specialist supervision. Experts also advise that lesions covering large areas of the conjunctiva may require mapping biopsies rather than a single sample, to avoid under-grading. Finally, given that conjunctival melanoma is rare and that fellowship-trained ocular oncologists practice at limited U.S. centers, referral to a specialist — verified through the American Board of Ophthalmology — is recommended for any lesion showing growth, thickening, or new vascularity rather than relying on a general eye exam alone.

References

1. Primary Acquired Melanosis of the Conjunctiva: Experience With 311 Eyes – PMC
2. Conjunctival Melanocytic Tumors – EyeWiki
3. Primary Acquired Melanosis (PAM) – All About Vision
4. Conjunctival Pigmented Lesions: Diagnosis and Management – American Academy of Ophthalmology
5. Conjunctival Primary Acquired Melanosis – Wills Eye Hospital
6. Moran CORE | Primary Acquired Melanosis (PAM) with Atypia
7. Primary Acquired Melanosis: Clinical, Histopathologic and OCT Correlation – PMC
8. Understanding Conjunctival Melanosis – Northwest Eye
9. Clinical Characterization of Primary Acquired Melanosis – IOVS
10. Conjunctival Melanoma: Origin From Primary Acquired Melanosis and Nevus – IOVS

Frequently Asked Questions

Is primary acquired melanosis cancer?

Not by itself. Primary acquired melanosis is a flat brown conjunctival lesion that may be benign or precancerous depending on whether atypia is present. According to PMC research on 311 eyes, PAM without atypia and with mild atypia showed 0% progression to melanoma, while severe atypia progressed in 13% of cases [1]. So a PAM diagnosis alone does not mean cancer. The biopsy grade determines risk. Conjunctival melanoma does arise from PAM in 71–74% of cases, which is why specialists track these lesions with photography and treat atypical ones [10].

What does primary acquired melanosis look like?

It usually appears as a single, flat, brown patch on the white part of one eye’s conjunctiva, without pain, cysts, or a raised bump. According to EyeWiki, it most frequently develops in middle-aged, light-skinned individuals [2][6]. The pigment may be light tan to dark brown and can shift in shape over months. Warning signs that warrant a prompt specialist visit include enlargement, darkening, new blood vessels, or a thickened nodule. A stable, flat patch graded without atypia is low risk, but any documented change should be re-evaluated by an ophthalmologist.

How is primary acquired melanosis diagnosed?

Diagnosis starts with a slit-lamp eye exam and baseline photography by an ophthalmologist. According to the American Academy of Ophthalmology, documenting change over time is central to managing pigmented conjunctival lesions [4]. Anterior segment OCT imaging can characterize lesion architecture [7]. The definitive answer comes from a biopsy, which a pathologist grades for atypia. Larger lesions may need mapping biopsies sampling multiple zones. In the US, a consultation runs roughly $150–$400 out of pocket, while a biopsy with pathology ranges $800–$2,500 depending on region and facility. Confirm whether your medical or vision plan covers the procedure.

How is PAM treated and what does it cost?

Treatment depends on the atypia grade. PAM without atypia is usually observed with photography every 6–12 months, since PMC data showed 0% progression [1]. PAM with severe atypia is treated with surgical excision plus cryotherapy or topical mitomycin C drops [4]. In the US, excision with cryotherapy commonly ranges $2,000–$6,000 before insurance, and a mitomycin C course runs about $300–$900 plus monitoring. As of 2026, no drug is FDA-approved specifically for PAM, so topical chemotherapy is used off-label under specialist supervision. Costs and insurance pre-authorization rules vary by state and carrier.

Can primary acquired melanosis turn into melanoma?

Yes, but the risk depends on atypia severity. According to PMC research, melanoma transformation at 10 years was estimated at 11–12% across observed and biopsied cases, with severe atypia driving most progression at 13% [1]. ARVO’s IOVS data shows conjunctival melanoma arises from PAM in 71–74% of cases [10]. Importantly, melanomas originating from PAM had a 9% melanoma-related death rate at 10 years, versus 35% for de novo tumors—so catching PAM early improves outcomes [10]. This is why monitoring and timely treatment of atypical lesions matter.

When should I see a specialist for an eye spot?

See an ophthalmologist within weeks if a brown conjunctival spot is enlarging, darkening, developing a raised nodule, growing new blood vessels, or spreading onto the cornea or eyelid. According to ARVO’s IOVS research, nodularity or thickening can signal transformation toward melanoma [10]. Because PAM-origin melanomas have far better survival when caught early, prompt referral matters. Do not rely on phone photo apps to assess eye lesions—they are not validated. Verify a physician’s credentials through the American Board of Ophthalmology’s online tool, and consider a fellowship-trained ocular oncologist for any growing or atypical lesion.